Acute mania: haloperidol dose and augmentation with lithium or lorazepam

Area of Science:

• Psychiatry
• Pharmacology
• Neuroscience

Background:

• Antipsychotic dosing for acute mania requires further investigation.
• The added antimanic efficacy of lithium-antipsychotic combinations over antipsychotics alone is not well established.
• The impact of lithium on antipsychotic dose requirements has not been previously studied.

Purpose of the Study:

• To investigate the efficacy of different haloperidol doses in acute mania.
• To determine if lithium or lorazepam enhances the antimanic effects of haloperidol.
• To explore the potential interaction between lithium and haloperidol dosage.

Main Methods:

• 63 acutely psychotic bipolar manic inpatients were enrolled in a double-blind study.
• Participants received either 25 mg/day or 5 mg/day of haloperidol for 21 days.
• Concomitant treatments included placebo, lithium, or lorazepam (4 mg/day).

Main Results:

• Higher haloperidol dose (25 mg/day) showed greater improvement and more side effects than the lower dose (5 mg/day).
• Lithium added to low-dose haloperidol significantly improved clinical response compared to low-dose haloperidol alone.
• Lorazepam (4 mg/day) did not enhance outcomes with low-dose haloperidol, nor did lithium or lorazepam improve outcomes with high-dose haloperidol.

Conclusions:

• Low-dose haloperidol (5 mg/day) alone is insufficient for most manic patients.
• Concomitant lithium administration provides a dose-dependent enhancement of haloperidol's antimanic efficacy.
• Lorazepam at 4 mg/day did not offer additional benefits when combined with low-dose haloperidol.